Hematologic Cancer Clinical Trial
— HYCVAOfficial title:
Hypnosis: a Path to Appeasement
Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. This tool can be used when patients are faced with chronic disorders (pain, anxiety, ...) or iatrogenic effects (nausea, asthenia, ...). The patient is referred to hypnosis care by the doctor, psychologist or paramedics who follow him, when they detect a need. Several scientific studies have shown the effectiveness of hypnosis in improving the quality of life of patients with breast cancer and in reducing pain during invasive procedures. On the other hand, in hematology, no research has measured the evolution of anxiety, over time, in patients receiving hypnotherapy.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients over 18 years old, fluent in French. - Patients starting hypnotherapy for anxiety disorders. - Anxiety score on the HADS scale (Hospital Anxiety and Depression Scale) greater than or equal to 8/21 - Patients with diffuse large cell B-cell lymphoma or follicular lymphoma, whatever the stage of the disease. - Diagnosis announcement less than 2 months old Exclusion Criteria: - Persons deprived of their liberty by a judicial or administrative decision - Adults subject to a legal protection measure |
Country | Name | City | State |
---|---|---|---|
France | Service MB1 - Hôpital Lyon Sud - HCL | Lyon | Pierre-Bénite |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evolution of anxiety | Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious. | Week 6 after 2 hypnosis sessions | |
Secondary | Evolution of anxiety before hypnotherapy and after 3 months of follow-up in hypnotherapy | Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious. | Month 3 after 3 hypnosis sessions | |
Secondary | Evolution of anxiety between D0 and M3 according to the type of lymphoma | Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : follicular lymphoma and diffuse large b-cell lymphoma. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious. | Month 3 after 3 hypnosis sessions | |
Secondary | Evolution of anxiety between D0 and W6 according to the type of lymphoma | Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : follicular lymphoma and diffuse large b-cell lymphoma. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious. | Week 6 after 2 hypnosis sessions | |
Secondary | Evolution of anxiety between D0 and W6 according to the gender of the patient | Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : man and woman. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious. | Week 6 after 2 hypnosis sessions | |
Secondary | Evolution of anxiety between D0 and M3 according to the gender of the patient | Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : man and woman. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious. | Month 3 after 3 hypnosis sessions | |
Secondary | Evolution of anxiety between D0 and W6 according to age category | Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : under 60 years old ans over 60 years old. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious. | Week 6 after 2 hypnosis sessions | |
Secondary | Evolution of anxiety between D0 and M3 according to age category | Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : under 60 years old ans over 60 years old. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious. | Month 3 after 3 hypnosis sessions |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04966156 -
Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT
|
N/A | |
Recruiting |
NCT05715047 -
Intervention for Fatigue in HCT Recipients
|
N/A | |
Recruiting |
NCT05142033 -
Avera Cancer Sequencing and Analytics Protocol (ASAP)
|
||
Completed |
NCT06053918 -
Research-Action in Hematology From Hospitalization to Home
|
||
Recruiting |
NCT05175508 -
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04822974 -
TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS
|
N/A | |
Not yet recruiting |
NCT06279585 -
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
|
N/A | |
Recruiting |
NCT05753501 -
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT05481502 -
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
|
N/A | |
Not yet recruiting |
NCT04412135 -
The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
|
||
Not yet recruiting |
NCT06377059 -
Early Detection of Complications During Immunotherapy for Haematological Malignancy
|
N/A | |
Completed |
NCT04235153 -
CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
|
||
Recruiting |
NCT05626764 -
QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
|
||
Active, not recruiting |
NCT04035447 -
Symptom Management for YA Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT05602168 -
Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance
|
N/A | |
Terminated |
NCT03955276 -
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
|
||
Recruiting |
NCT03091933 -
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01792882 -
Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
|
||
Active, not recruiting |
NCT05493800 -
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
|
Phase 2 | |
Active, not recruiting |
NCT05690230 -
Improving Patient Experience: BMBA
|
N/A |